Table 5.

Randomized trials of rasburicase

StudyYearPatients (n)PopulationGroup 1Group 2End PointSuperior Group
Cortes et al. (61)a2010183Adults at risk for TLSRasburicase, 0.20 mg/kg per d for 5 dAllopurinol, 300 mg/d for 5 dUric acid <7.5 mg/dl at 3–7 d1
Malaguarnera et al. (68)200938Hyperuricemic elderly patientsRasburicase, 4.5 mg for 1 dosePlaceboChange in uric acid at 1 wk1
Kikuchi et al. (92)200930Japanese children at risk for TLSRasburicase, 0.20 mg/kg per d for 5 dRasburicase, 0.15 mg/kg per d for 5 dSustained reduction in uric acid to <6.5 mg/dl (age <13 yr) or <7.5 mg/dl (age ≥13 yr)1
Ishizawa et al. (93)200950Japanese adults at risk for TLSRasburicase, 0.20 mg/kg per d for 5 dRasburicase, 0.15 mg/kg per d for 5 dSustained reduction of uric acid <7.5 mg/dlEquivalent
Goldman et al. (77)200152Children at risk for TLSRasburicase, 0.20 mg/kg per d for 5–7 dAllopurinol, 300 mg every 8 h for 5–7 dArea under the uric acid curve over 5 d1
  • TLS, tumor lysis syndrome.

  • a Study also contained a rasburicase and sequential allopurinol group (n=92).